An active-control trial of lamotrigine monotherapy for partial seizures

Neurology

Volumn 51, Issue 4, 1998, Pages 1018-1025

  Gilliam, Frank ^a   Vazquez, B ^b   Sackellares, J C ^c   Chang, G Y ^d   Messenheimer, J ^e   Nyberg, J ^e   Risner, M E ^e   Rudd, G D ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d LAC USC MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0031684166     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.4.1018     Document Type: Article

References (39)

1. Meldrum B, Leach M. The mechanisms of action of lamotrigine. Rev Contemp Pharmaeother 1994;5:107-114.
2. Zona C, Avoli M. Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 1997;38: 522-525.
3. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992;13:107-112.
4. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996;307:113-116.
5. Wegerer JV, Heβlinger B, Berger M, Walden J. A calcium antagonist effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 1997;7:77-81.
6. Mattson RH, Cramer JA, Collins JF, et al. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology 1996;47:68-76.
7. Hart YM, Sander JWAS, Johnson AL, Shorvon SD for the NGPSE. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990;336:1271-1274.
8. Beghi E, Tognoni G (Collaborative Group for the Study of Epilepsy principal investigators). Prognosis of epilepsy in newly referred patients: a multicenter prospective study. Epilepsia 1988;29:236-243.
9. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primodone in partial and secondarily generalized tonic clonic seizures. N Engl J Med 1985;313:145-151.
10. Mattson RH, Cramer JA, Collins JF, and the Dept. of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-771.
11. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-121.
12. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-2291.
13. Binnie CD, Van Wieringen A, Meijer JWA, Peck AW, DeVries J. Double-blind crossover trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsy Res 1989;4:222-229.
14. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-363.
15. Sander SWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-226.
16. Loiseau P, Yuen AWC, Duche B, Menager T, Arne-Bes MC. A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-145.
17. Schapel GJ, Beran RG, Vajda FJE, Berkovic SF, Mashford ML, Dunagan FM. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-453.
18. Schachter SC, Leppik IE, Matsuo F, et al. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 1995;8:201-209.
19. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345(8948):476-479.
20. Steiner TJ , Yuen AWC. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy. Epilepsia 1994;35(suppl 7):61. Abstract.
21. Reunanen M, Dam M, Yuen AWC. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-155.
22. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989;30(suppl 1):S57-S63.
23. French JA. What trials, which designs? Epilepsia 1997;38: 263-265.
24. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991;32: 716-721.
25. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993;43:688-692.
26. Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology 1997:49:746-752.
27. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294-300.
28. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1989;30:389-399.
29. van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bulletin of the International Statistical Institute 1960;37:351-361.
30. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997;38(suppl 9):S21-S31.
31. Mockel V. Clinical trials for antiepileptic drugs: from add-on to monotherapy and dose-related designs. Drug Inform J 1997;31:685-695.
32. Valproic acid (Depakene) Product Information. Abbott Laboratories, North Chicago, IL, 1997.
33. Yau MK, Grasela TH, Fiedler-Kelly J, et al. Population pharmacokinetics of lamotrigine (Lamictal) from three add-on controlled clinical trials in adult patients with epilepsy. Epilepsia 1993;34(suppl 6):68. Abstract.
34. Gidal BE, Rutecki P, Shaw R, Maly MM, Collins DM, Pitterle ME. Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res 1997;28:207-211.
35. Manasco P, Mullens L, Matsuo F. Skin rash associated with Lamictal: incidence, time to onset, and risk factors. Epilepsia 1996;37(suppl 5):164. Abstract.
36. Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996;37(suppl 6):S17-S22.
37. Lamotrigine (Lamictal) Product Information. Glaxo Wellcome, Inc., Research Triangle Park, NC, 1998.
38. Kramlinger K, Phillips KA, Post RM. Rash complicating carbamazepine treatment. J Clin Psychopharmacol 1994;14:408-413.
39. Langtry HD, Wagstaff AJ. Management of epilepsy; defining the role of lamotrigine. Disease Manage Health Outcomes 1997;1:254-270.